GeneDx Holdings Corp. (WGS) Income Statement
WGS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsWGS revenue and net income
Where WGS's revenue goes
2025Each bar shows an amount and its share of revenue. WGS kept −4.9% of revenue as net income.
WGS profit margins
WGS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +40.0% | +22.1% | +19.0% | — |
| Gross profit | +53.4% | — | +136.5% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | +460.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
WGS quarterly EPS vs estimates
GeneDx beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: October 27, 2026 (estimate $0.07).
WGS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M | $179.3M | $196.2M |
| Cost of revenue | $129.4M | $111.1M | $112.6M | $261.4M | $228.8M | $175.3M | $113.4M |
| Gross profit | $298.2M | $194.4M | $90.0M | −$26.8M | −$16.6M | $4.0M | $82.8M |
| Research & development | $72.0M | $45.7M | $58.3M | $86.2M | $105.2M | $72.7M | $34.9M |
| Sales, general & admin | $239.2M | $168.5M | $194.7M | $338.2M | $318.7M | $163.9M | $68.8M |
| Total operating expenses | $311.2M | $217.6M | $270.6M | $640.9M | $429.5M | $246.0M | $113.2M |
| Operating income | −$11.8M | −$23.2M | −$180.6M | −$667.7M | −$446.1M | −$242.0M | −$30.4M |
| Interest income | — | — | — | $2.5M | $79,000 | $506,000 | $988,000 |
| Interest expense | $2.5M | $3.0M | — | $3.2M | $2.8M | $2.5M | $783,000 |
| Income before taxes | −$21.1M | −$52.6M | −$176.7M | −$598.0M | −$245.4M | −$241.3M | −$29.7M |
| Income taxes | −$116,000 | −$343,000 | −$926,000 | −$49.1M | $21.6M | $5.1M | $1.3M |
| Net income | −$21.0M | −$52.3M | −$175.8M | −$549.0M | −$245.4M | −$241.3M | −$29.7M |
| EBITDA | $6.6M | −$27.6M | −$136.5M | −$398.2M | −$220.7M | −$227.1M | −$22.5M |
| EPS (diluted) | $1.40 | $0.25 | −$6.18 | −$22.86 | −$17.50 | $0.00 | — |
| Gross margin | 69.7% | 63.6% | 44.4% | −11.4% | −7.8% | 2.2% | 42.2% |
| Operating margin | −2.8% | −7.6% | −89.2% | −284.5% | −210.3% | −134.9% | −15.5% |
| Net margin | −4.9% | −17.1% | −86.8% | −233.9% | −115.6% | −134.6% | −15.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M | $102.3M | $121.0M | $116.7M | $102.7M | $87.1M | $95.6M | $76.9M | $70.5M | $62.4M | $57.4M | $53.3M |
| Cost of revenue | $36.2M | $34.0M | $42.1M | $32.2M | $31.8M | $28.6M | $29.4M | $29.0M | $27.6M | $25.0M | $26.7M | $28.0M |
| Gross profit | $78.2M | $68.2M | $78.9M | $84.5M | $70.9M | $58.5M | $66.2M | $47.8M | $43.0M | $37.4M | $30.8M | $25.3M |
| Research & development | $19.7M | $19.8M | $24.0M | $19.8M | $14.9M | $12.6M | $11.6M | $11.7M | $10.7M | $11.6M | $12.2M | $14.3M |
| Sales, general & admin | $72.7M | $74.6M | $47.3M | $67.2M | $46.4M | $50.5M | $45.0M | $43.2M | $42.1M | $39.5M | $42.2M | $42.9M |
| Total operating expenses | $95.7M | $94.4M | $92.6M | $87.8M | $61.9M | $63.0M | $57.4M | $55.6M | $53.5M | $51.1M | $56.4M | $68.2M |
| Operating income | −$17.5M | −$26.2M | −$13.7M | −$3.3M | $9.0M | −$4.6M | $8.8M | −$7.8M | −$10.6M | −$13.7M | −$25.6M | −$43.0M |
| Interest income | — | — | — | — | — | — | — | — | — | — | — | $1.1M |
| Interest expense | $1.2M | $717,000 | $520,000 | $562,000 | $817,000 | $640,000 | $698,000 | $843,000 | $894,000 | $597,000 | $978,000 | — |
| Income before taxes | −$18.3M | −$62.4M | −$18.2M | −$7.4M | $10.6M | −$6.1M | $5.4M | −$8.4M | −$29.4M | −$20.3M | −$26.2M | −$42.5M |
| Income taxes | $518,000 | $897,000 | −$564,000 | $247,000 | −$246,000 | $447,000 | −$24,000 | −$47,000 | −$190,000 | −$82,000 | −$411,000 | −$172,000 |
| Net income | −$17.7M | −$63.3M | −$17.7M | −$7.6M | $10.8M | −$6.5M | $5.4M | −$8.3M | −$29.2M | −$20.2M | −$25.8M | −$42.3M |
| EBITDA | −$10.4M | −$54.9M | −$10.8M | −$352,000 | $17.6M | $236,000 | $11.7M | −$1.6M | −$23.3M | −$14.5M | −$19.1M | −$26.0M |
| EPS (diluted) | $0.01 | −$0.28 | $0.14 | $0.49 | $0.50 | $0.27 | $0.64 | $0.04 | −$0.10 | −$0.33 | −$0.69 | −$0.82 |
| Gross margin | 68.4% | 66.7% | 65.2% | 72.4% | 69.0% | 67.1% | 69.2% | 62.2% | 60.9% | 59.9% | 53.6% | 47.4% |
| Operating margin | −15.3% | −25.6% | −11.3% | −2.8% | 8.7% | −5.2% | 9.2% | −10.1% | −15.0% | −21.9% | −44.7% | −80.6% |
| Net margin | −15.5% | −61.9% | −14.6% | −6.5% | 10.5% | −7.5% | 5.7% | −10.8% | −41.4% | −32.4% | −44.9% | −79.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in WGS's financial statements (latest annual report filed February 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
WGS financial results
In fiscal year 2025 (ended December 31, 2025), GeneDx reported revenue of $427.5 million, up 40.0% from the year before. It had a net loss of $21.0 million, a net profit margin of −4.9%. Diluted earnings per share came to $1.40. Over five years revenue grew at an average rate of 19.0% a year.
See the WGS stock overview for the latest quote and news, or the WGS chart for price history and technical indicators.
WGS income statement FAQ
What is GeneDx's annual revenue?
GeneDx reported total revenue of $427.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 40.0% from $305.4 million the previous year.
Is GeneDx profitable?
No. GeneDx reported a net loss of $21.0 million in fiscal 2025, a net profit margin of −4.9%; its operating margin was −2.8%.
What is GeneDx's gross margin?
GeneDx's gross margin was 69.7% in fiscal 2025: for every $100 of revenue, GeneDx kept $70 after the direct cost of its products and services.
How much does GeneDx spend on research and development?
GeneDx spent $72.0 million on research and development in fiscal 2025, 16.8% of revenue.
How fast is GeneDx growing?
Revenue grew 19.0% a year on average over the last five fiscal years, from $179.3 million to $427.5 million.
What are GeneDx's earnings per share?
GeneDx earned $1.40 per diluted share in fiscal 2025, compared with $0.25 a year earlier.
When will GeneDx report its next earnings?
GeneDx is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes.
When does GeneDx's fiscal year end?
GeneDx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 23, 2026.